S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

ESSA Pharma Stock Forecast, Price & News

-1.21 (-9.40%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
229,411 shs
Average Volume
374,610 shs
Market Capitalization
$512.81 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

ESSA Pharma logo

About ESSA Pharma

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$4.41 per share


Net Income
$-36.81 million
Pretax Margin




Free Float
Market Cap
$512.81 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.03 out of 5 stars

Medical Sector

584th out of 1,388 stocks

Pharmaceutical Preparations Industry

274th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions

Is ESSA Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ESSA Pharma stock.
View analyst ratings for ESSA Pharma
or view top-rated stocks.

How has ESSA Pharma's stock price been impacted by COVID-19?

ESSA Pharma's stock was trading at $4.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EPIX stock has increased by 186.5% and is now trading at $11.66.
View which stocks have been most impacted by COVID-19

Are investors shorting ESSA Pharma?

ESSA Pharma saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 937,100 shares, a decline of 25.0% from the October 31st total of 1,250,000 shares. Based on an average daily volume of 296,400 shares, the short-interest ratio is presently 3.2 days. Currently, 5.6% of the company's stock are short sold.
View ESSA Pharma's Short Interest

When is ESSA Pharma's next earnings date?

ESSA Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for ESSA Pharma

How were ESSA Pharma's earnings last quarter?

ESSA Pharma Inc. (NASDAQ:EPIX) announced its earnings results on Thursday, November, 18th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03.
View ESSA Pharma's earnings history

What price target have analysts set for EPIX?

4 equities research analysts have issued 12 month price targets for ESSA Pharma's stock. Their forecasts range from $22.00 to $50.00. On average, they expect ESSA Pharma's share price to reach $34.67 in the next twelve months. This suggests a possible upside of 197.3% from the stock's current price.
View analysts' price targets for ESSA Pharma
or view top-rated stocks among Wall Street analysts.

Who are ESSA Pharma's key executives?

ESSA Pharma's management team includes the following people:
  • Dr. David Ross Parkinson, Pres, CEO & Director (Age 71, Pay $788.6k)
  • Mr. Peter A. Virsik M.B.A., M.S., Exec. VP & COO (Age 50, Pay $615.59k)
  • Dr. Alessandra Cesano M.D., Ph.D., Chief Medical Officer
  • Mr. David S. Wood C.M.A., CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer (Age 64)
  • Chandtip Chandhasin, Exec.
  • Erica Osbourne, Exec.
  • Erin Rudsinski, Exec.
  • Leah Dimascio, Exec.
  • Loleta Harris, Exec.
  • Neil Thapar, Exec.

What other stocks do shareholders of ESSA Pharma own?

What is ESSA Pharma's stock symbol?

ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX."

Who are ESSA Pharma's major shareholders?

ESSA Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Bellevue Group AG (11.45%), Janus Henderson Group PLC (7.91%), BVF Inc. IL (6.48%), RTW Investments LP (6.00%), Citadel Advisors LLC (1.56%) and BioImpact Capital LLC (1.55%). Company insiders that own ESSA Pharma stock include Franklin M Berger and Growth N V Biotech.
View institutional ownership trends for ESSA Pharma

Which institutional investors are selling ESSA Pharma stock?

EPIX stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Morgan Stanley, Sphera Funds Management LTD., Ensign Peak Advisors Inc, Schonfeld Strategic Advisors LLC, UBS Group AG, Citadel Advisors LLC, and Advisor Group Holdings Inc..
View insider buying and selling activity for ESSA Pharma
or view top insider-selling stocks.

Which institutional investors are buying ESSA Pharma stock?

EPIX stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Janus Henderson Group PLC, BioImpact Capital LLC, Two Sigma Advisers LP, Two Sigma Investments LP, BVF Inc. IL, Rhenman & Partners Asset Management AB, and Millennium Management LLC. Company insiders that have bought ESSA Pharma stock in the last two years include Franklin M Berger, and Growth N V Biotech.
View insider buying and selling activity for ESSA Pharma
or or view top insider-buying stocks.

How do I buy shares of ESSA Pharma?

Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ESSA Pharma's stock price today?

One share of EPIX stock can currently be purchased for approximately $11.66.

How much money does ESSA Pharma make?

ESSA Pharma has a market capitalization of $512.81 million. The company earns $-36.81 million in net income (profit) each year or ($0.97) on an earnings per share basis.

How many employees does ESSA Pharma have?

ESSA Pharma employs 25 workers across the globe.

What is ESSA Pharma's official website?

The official website for ESSA Pharma is www.essapharma.com.

Where are ESSA Pharma's headquarters?

ESSA Pharma is headquartered at 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5.

How can I contact ESSA Pharma?

ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962, via email at [email protected], or via fax at 604-738-4080.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.